India Demands Prior Government Approval for High-Risk Prescription Drug Ads

The Indian government has just issued a crucial draft notification, the Drugs (Amendment) Rules, 2026, demanding mandatory prior approval from the Central Government for all advertisements of prescription drugs, especially those with high abuse potential falling under Schedules H, H1, and X. Published in the Official Gazette on September 28, this move aims to clamp down on unchecked drug promotions and safeguard public health. The public now has a 30-day window to provide feedback on these proposed changes, which are expected to take effect upon final publication. This isn't happening in a vacuum. The Indian pharmaceutical industry has long operated under a voluntary marketing code, the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which critics argue has been largely ineffective against widespread unethical marketing practices, including lavish gifts to doctors. Just yesterday, October 8, 2026, the Supreme Court of India stepped in, directing the Union government to form an expert committee within two weeks to finally craft statutory (legally binding) regulations for pharmaceutical marketing, pushing for greater transparency and accountability. This overlapping legal pressure underscores the urgent need to curb misleading advertisements, particularly for potent drugs like GLP-1 receptor agonists, which have seen a surge in online promotion contributing to self-medication and antibiotic misuse. As the public feedback period progresses, all eyes are on the Central Government to see how swiftly these amendments will be finalized and enforced. The proposed rules include significant penalties for non-compliance, such as marketing bans and hefty fines, with a new 'Ethics Compliance Officer' envisioned to oversee implementation. This dual-pronged effort by both the executive and judiciary signals a profound shift towards a more rigorously regulated pharmaceutical advertising landscape in India, aiming to protect consumers from potentially harmful and deceptive promotions. The pharmaceutical industry will need to quickly adapt to a much stricter regulatory environment.